Krónikus C hepatitis klinikopatológiai képének alakulása 6 és 12 hónapos interferon-alfa kezelést követóen.

Translated title of the contribution: Histo-pathological evaluation of response to 6 and 12 months of interferon alpha therapy

K. Jármay, G. Karácsony, Z. Ozsvár, I. Nagy, J. Lonovics, Z. Schaff

Research output: Contribution to journalReview article

Abstract

BACKGROUND AND AIMS: Interferon-alfa (IFN-alfa) has recently been introduced for chronic C hepatitis treatment; however, the response rate is merely 25-50%. The aims of this follow-up study were to compare the efficacy of 6 and 12-month IFN-alfa treatment via liver biopsy scores and to evaluate the correlation with the biochemical response. PATIENTS AND METHODS: 20 chronic C hepatitis patients were studied. 10 patients received IFN-alfa therapy for 6 months, and 10 for 12 months (3 million units three times a week). Liver biopsy material was taken before and after therapy. RESULTS: There was a significant serum alanine aminotransferase (ALT) level improvement in both groups, but a significant histological improvement in necroinflammatory activity (grade) occurred only in the 12-month group. The Chevallier stage scores demonstrated a significant progression in both groups. CONCLUSIONS: 12-month IFN-alfa treatment affords a better response in the liver histology grade and serum ALT level, but not the stage; a normal ALT does not guarantee hepatitis inactivity. Liver biopsies appear indispensable for monitoring the fibrotic changes in chronic C hepatitis.

Translated title of the contributionHisto-pathological evaluation of response to 6 and 12 months of interferon alpha therapy
Original languageHungarian
Pages (from-to)875-881
Number of pages7
JournalOrvosi hetilap
Volume139
Issue number15
Publication statusPublished - Apr 12 1998

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Histo-pathological evaluation of response to 6 and 12 months of interferon alpha therapy'. Together they form a unique fingerprint.

  • Cite this